Printer Friendly

RHONE-POULENC RORER DEVELOPING A NEW GENERATION ANTI-MALARIA DRUG IN RESPONSE TO A SERIOUS PUBLIC HEALTH PROBLEM

 RHONE-POULENC RORER DEVELOPING A NEW GENERATION ANTI-MALARIA DRUG
 IN RESPONSE TO A SERIOUS PUBLIC HEALTH PROBLEM
 COLLEGEVILLE, Pa., Aug. 27 /PRNewswire/ -- Rhone-Poulenc Rorer (NYSE: RPR) announced today it is currently developing a new anti- malarial drug, Paluther(TM) (artemether).
 Marketing is expected in 1993.
 Paluther (artemether) is from the chemical family artemisinin. The active ingredient is a semi-synthetic derivative from the Chinese plant Qing Hao, used for more than 2,000 years in traditional Chinese medicine.
 Paluther will be indicated for severe malaria and will represent a new generation of anti-malarial drugs, which is especially important since the mosquito-carried parasites (mostly plasmodium falciparum) have become increasingly resistant to the current anti-malarial drugs such as chloroquine, quinine and some of the more recently introduced drugs.
 In clinical trials in severely ill patients, Paluther acts faster than other anti-malarials and is administered intramuscularly (injected). This offers hope that this new drug may be able to improve survival, particularly among children, who are frequently the most severely affected by malaria.
 The World Health Organization (WHO), estimates that there are 100 million cases of malaria annually leading to approximately 2 million deaths per year. At least 40 percent of the world's population is at risk, including business travelers and tourists to tropical countries.
 Paluther complements Rhone-Poulenc Rorer's commitment to the treatment of tropical diseases and parasitology.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, marketing and manufacturing of human pharmaceuticals. The company reported sales of $3.8 billion in 1991 and plans to invest more than $500 million in research and development in 1992.
 /delval/
 -0- 8/27/92
 /CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871/
 (RPR) CO: Rhone-Poulenc Rorer ST: Pennsylvania IN: MTC SU:


MK-CC -- PH017 -- 3927 08/27/92 11:55 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 27, 1992
Words:293
Previous Article:CURATEK ANNOUNCES FDA APPROVAL OF NEW THERAPY FOR BACTERIAL VAGINOSIS
Next Article:INTERMAGNETICS GENERAL CORP.'S SUPERCONDUCTORS CONTRIBUTE TO SUCCESSFUL RESULTS IN MAJOR TEST OF SUPERCONDUCTING SUPER COLLIDER MAGNETS
Topics:


Related Articles
TILADE APPROVED BY FDA; FISONS ANNOUNCES CO-PROMOTION AGREEMENT WITH RHONE-POULENC RORER
TOLL-FREE NUMBER AVAILABLE FOR TAXOTERE(R) CLINICAL TRIALS
NEW MAALOX(R) PRODUCTS FROM RHONE-POULENC RORER DEMONSTRATE GROWTH BEYOND ANTACIDS
BREAST CANCER CLINICAL TRIALS OPEN IN READING AREA; INFORMATION AVAILABLE VIA TOLL-FREE NUMBER
RHONE-POULENC RORER APPLIES FOR REGULATORY APPROVALS FOR TAXOTERE(R) (DOCETAXEL) NEW ANTI-CANCER DRUG IN UNITED STATES, CANADA, AND EUROPE
A NEW CLINICAL TRIAL FOR NON-SMALL CELL LUNG CANCER IS STARTED AS PART OF TAXOTERE(R) RESEARCH BY RHoNE-POULENC RORER
CAMPTO(R) (irinotecan/CPT-11) RECEIVES REGULATORY APPROVAL IN FRANCE FOR TREATMENT OF ADVANCED COLORECTAL CANCER
RHONE-POULENC RORER SUBMITS MARKETING APPLICATION IN EUROPEAN UNION FOR RILUTEK(R) (riluzole)
Rhone-Poulenc Rorer Submits New Drug Application for One of First CFC-Free Inhaled Corticosteroids for Asthma
FDA Advisory Panel Recommends Approval of Synercid(R) for Treatment Of Severe to Life-Threatening Bacterial Infections

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters